Abstract. Previous experimental and clinical data have indicated that tumour cell proliferation is associated with angiogenesis; in addition, an increased microvascular density (MVD) of tumours has been associated with poor prognosis in solid and haematological malignancies. However, limited data exists regarding the association between tumour cell proliferation and angiogenesis in primary tumour tissue from pancreatic ductal adenocarcinoma (PDAC) patients; therefore, the present study aimed to investigate this association. A series of 31 PDAC patients with stage Tumour (T) [2] [3] Node (N) 0-1 Metastasis (M) 0 were recruited into the present study and subsequently underwent surgery. PDAC tissue and adjacent normal tissue (ANT), resected during surgery, were evaluated using immunohistochemistry and image analysis methods to determine MVD, endothelial area (EA) and Ki-67 expression, which is an indicator of cell proliferation rate. The results demonstrated a correlation between the above parameters with each other as well as the main clinico-pathological features of PDAC. Significant differences were identified in MVD, EA and Ki-67 proliferation index between PDAC and ANT. It was demonstrated that MVD, EA and Ki-67 proliferation index were significantly correlated with each other in tumour tissue (r=0.69-0.81; P=0.001-0.003). However, no other significant correlations were identified. These data therefore suggested that angiogenesis and cell proliferation rate were significantly increased in PDAC compared with ANT, which provides a biological basis for the potential use of novel combinations of angiogenesis inhibitors and anti-proliferative chemotherapeutic drugs in the treatment of PDAC.
Introduction
Tumour tissue angiogenesis is often evaluated by determining microvascular density (MVD) and endothelial area (EA) (1) (2) (3) . MVD and EA have been experimentally proposed to be biomarkers associated with biological aggressiveness and clinical outcome in animal and human malignancies. In regards to pancreatic cancer, it has been established that angiogenesis has a role in its development and progression (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In addition, Ki-67 expression is an important parameter for biological aggressiveness and prognosis in tumour tissue; Ki-67 antigens are initially expressed in S-phase and increase throughout S-and G 2 -phase until they reach their peak expression during mitosis. Following division, cells progress into G 1 -phase with high levels of Ki-67 antigen, which gradually decrease during this phase and are low or no longer expressed in cells in prolonged G 1 . Therefore, Ki-67 protein is expressed in proliferating cells throughout the cell cycle, but not in quiescent (G 0 ) cells (18) (19) (20) . Ki-67 may be used as a proliferation index to characterise proliferating and non-proliferating tumour cells (21, 22) ; however, no data have been reported regarding the correlation between MVD or EA and Ki-67 proliferation index in pancreatic ductal adenocarcinoma (PDAC). The aim of the present study was to analyse MVD, EA and Ki-67 expression in proliferating cells in a series of 31 human PDAC tissues and in their corresponding adjacent normal tissue (ANT) in order to evaluate differences in these tissue parameters between normal and malignant tissue. In addition, the present study aimed to evaluate the potential correlation of these factors with each other. Furthermore, the correlation between each analysed tissue index and the primary clinico-pathological features of PDAC were investigated.
Patients and methods
Patients. The clinico-pathological features of selected patients are summarised in Table I . A total of 31 PDAC patients (PDACPs) underwent potentially curative surgical resection at the Clinical Surgery Unit, University of Catanzaro 'Magna Graecia' Medical School (Catanzaro, Italy). Surgical approaches used included pancreaticoduodenectomy, distal pancreatectomy and total pancreatectomy with lymph node dissection. Tumour tissues and ANT were resected from patients and tumour tissues were staged according to the American Joint Committee on Cancer classification guidelines (7th edition) and the World Health Organization classification guidelines (2000 version) for pathologic grading (23, 24) . Computed tomography (CT) was conducted on a Somatom Sensation CT scanner (Siemens AG, Munich, Germany) to confirm that all patients did not have distant metastases and ten patients underwent neo-adjuvant therapy with Gemcitabine or Folfirinox prior to surgery. The present study was approved by the Ethics Committee of 'Mater Domini' Hospital, 'Magna Graecia' University (Catanzaro, Italy). Full signed informed consent was obtained from each patient enrolled in the present study, including the authorisation to utilise each tissue sample for experimental studies.
Immunohistochemistry. For the evaluation of MVD, EA and Ki-67 proliferation index in PDAC tissue and ANT, a three-layer biotin-avidin-peroxidase system was utilised, as previously described (25) . In brief, 4-µm thick serial sections of formalin-fixed and paraffin-embedded tumour samples and the corresponding ANT (2 of each sample) were deparaffinised. Formalin and paraffin were purchased from Bio Optica Milano SpA, (Milan, Italy). For antigen retrieval, sections were then microwaved at 500 W for 10 min; following which, endogenous peroxidase activity was blocked with 3% hydrogen peroxide solution (Dako, Glostrup, Denmark). Subsequently, adjacent sections were incubated with the mouse monoclonal anti-CD31 antibodies (dilution, 1:40; JC70a; Dako) for 30 min at room temperature and mouse monoclonal anti-Ki-67 (dilution, 1:100; MIB-1; Immunotech, Inc., Marseilles, France) for 1 h at room temperature. The bound antibodies were visualised using a biotinylated horse anti-mouse IgG (H+L) secondary antibody (dilution, 1:100; BA-2000; Vector Laboratories, Inc., Burlingame, CA, USA) incubated for 1 h at room temperature, followed by avidin-biotin peroxidase complex and NovaRED (Vector Laboratories, Inc.). Nuclear counterstaining was performed using Gill's haematoxylin no. 2 (Polysciences, Inc., Warrington, PA, USA). For the negative controls, slides were incubated with secondary antibodies and primary antibody was omitted.
Morphometrical assay.
A Quantimet 500 image analysis system (Leica Microsystems GmbH, Wetzlar, Germany) with a connected Nikon Eclipse E400 Biological Microscope (Nikon Corporation, Tokyo, Japan) was employed. The five most vascularised areas ('hot spots') were selected at low magnification and the individual vessels (Fig. 1A) and Ki-67 proliferation index (Fig. 1B and C) were counted at x400 magnification (0.19 mm 2 area) in tumour tissue and ANT. A method of morphometric evaluation was used as described in a previous study (26) . Single red-stained endothelial cells, endothelial cell clusters and microvessels, clearly separated from adjacent microvessels, tumour cells, normal epithelial cells and other connective tissue elements were also counted. The immunostained area was evaluated identifying and manually delimiting the perimeter of each red immunostained area in a field of 0.19 mm 2 on the computer, then the software calculated the delimited area. In tumour tissue, areas of necrosis were not included in the counting area. Single red-stained endothelial cells were also evaluated in terms of immunostained area at x400 magnification (0.19 mm 2 area) (25) . Ki-67 expression was determined in corresponding areas to MVD 'hot spots' and only specific red nuclear staining was considered. The number of MIB-1 positively-stained nuclei was counted at x400 magnification (0.19 mm 2 area). The fraction of Ki-67-positive cells was calculated as the ratio of positively-stained tumour cells to all tumour cells. Furthermore, morphological detail, including the microvessel, its wall and the red blood cells in the lumen. Notably, the diameter of the lumen was very small compared with the red proliferating nuclei that were clearly visible near the microvessel. This was observed at x1,000 magnification in oil (Fig. 1D) .
Statistical analysis. Significant differences in the angiogenic indexes and Ki-67-positive fraction between PDAC and ANT were assessed using the Student's t-test. Linear correlations among MVD, EA and Ki-67 proliferation index were compared with each other and were quantified using the Pearson's correlation coefficient (r). Correlations among the MVD, EA and Ki-67 proliferation index groups and the main clinico-pathological features were analysed using the Chi-square test. Values are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference between values. All statistical analyses were performed using the SPSS statistical software package, version 20.0 (IBM SPSS, Armonk, NY, USA).
Results
All the tissue parameters evaluated, including MVD, EA and Ki-67 proliferation index, were compared between PDAC Values are presented as the mean ± standard deviation and statistical comparisons were performed using the Student's t-test. Results were counted in highly vascularised 'hot spots' at x400 magnification (0.19 mm 2 area; n=5). MVD, microvascular density; EA, endothelial area; ANT, adjacent normal tissue; PDAC, pancreatic ductal adenocarcinoma.
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tissue and ANT; the results are reported in Table II . The number of microvessels and EA were significantly higher in PDAC tissue (27±8 and 186.06±65.89 µ 2 , respectively) compared with the corresponding values in ANT (8±4 and 73.12±27.88 µ 2 ; P= 0.001 and P= 0.003, respectively). In addition, a significantly higher number of Ki-67-positive proliferative cells were observed in PDAC tissue compared with ANT (66±25 vs. 15±6; P=0.001) (Table II) . Immunohistochemical staining was performed using anti-Ki-67 antibodies and the evaluation at x1,000 magnification in oil demonstrated that in highly vascularised cancer tissue, red-immunostained proliferating nuclei were highly expressed and were primarily located in perivascular position (Fig. 1D) .
As shown in Fig. 2 
Discussion
Previous studies have demonstrated that angiogenesis and Ki-67-positive fraction are essential for the development and progression of tumours (27) (28) (29) (30) (31) . In addition, numerous studies have suggested that increased tissue MVD and Ki-67 proliferation index, which were individually assessed, were correlated with a poor prognosis in PDACP (21, 22) . However, studies into PDAC are limited and no data have been previously published regarding the correlation between MVD, EA angiogenic indexes and Ki-67 fraction in PDAC. The results of the present study demonstrated that MVD, EA and Ki-67 proliferation index were all significantly increased in PDAC tissue compared with ANT; in addition, it was revealed that in tumour tissue, these parameters were increased in parallel to each other. Of note, a close spatial association was observed between proliferating tumour cells and microvessels, as determined using image analysis data in the present study; this therefore indicated an anatomical association between neovessel formation and tumour cell proliferation. In addition, this anatomical link may be supported by the overexpression of several angiogenic cytokines, including vascular endothelial growth factor, fibroblast growth factor, thymidine phosphorylase and tryptase, which have been previously demonstrated to be present in PDAC tissue (32) (33) (34) (35) . These cytokines, secreted from tumoral and stromal cells, have a role in the autocrine and paracrine growth stimulation of tumoral and endothelial cells (36) (37) (38) .
In conclusion, the data presented in the current study suggested a pre-clinical background for the future evaluation of novel therapeutic treatments, which combine angiogenesis inhibitors and anti-proliferative chemotherapeutic drugs for PDAC. The study demonstrated that in association with angiogenesis, MVD, EA and Ki-67 proliferation index, are significantly correlated to each other in PDAC tumour tissues, and were significantly increased in these tissues compared with levels in normal tissues. Following future confirmation of the data, the analyzed biomarkers may identify an integrated panel of clinical aggressiveness which may be useful in the future to select patients who are suitable to receive potential adjuvant treatment. 
